Effect of gut microbiota on LPS-induced acute lung injury by regulating the TLR4/NF-kB signaling pathway

Tang, Jia; Xu, Lingqi; Zeng, Yiwen; Gong, Fang

doi:10.1016/j.intimp.2020.107272

Cited by 257 publications

(164 citation statements)

References 36 publications

Supporting

Mentioning

133

Contrasting

Unclassified

Order By: Relevance

“…Gut microbiota and respiratory diseasesExposure to antibiotics during the first year of life is linked to asthma in early childhood, which may be associated with antibiotic-induced gut dysbiosis in Bifidobacterium, Lactobacillus and fecal organic acids (especially acetate)SynbioticsSynbiotics reduced the incidence of enteritis and VAP in sepsis patients by improving the gut microbiota , and Actinomycetes decreased and Proteobacteria increased FMT FMT attenuated LPS-induced ALI by improving the gut microbiota to inhibit the TLR4/NF-κB signaling pathways[5] ARDS Human Gut microbiota translocation to the lungs Translocation of gut microbiota to the lungs may be involved in the pathogenesis of ARDS…”

mentioning

confidence: 99%

Gut microbiota and bronchopulmonary dysplasia

Yang

Dong

2021

Pediatric Pulmonology

View full text Add to dashboard Cite

Bronchopulmonary dysplasia is a relatively common and severe complication of prematurity, and its pathogenesis remains ambiguous. Revolutionary advances in microbiological analysis techniques, together with the growing sophistication of the gut-lung axis hypothesis, have resulted in more studies linking gut microbiota dysbiosis to the occurrence and development of bronchopulmonary dysplasia. The present article builds on current findings to examine the intrinsic associations between gut microbiota and bronchopulmonary dysplasia. Gut microbiota dysbiosis may insult the intestinal barrier, triggering inflammation, metabolic disturbances, and malnutrition, consequences of which might impact bronchopulmonary dysplasia by altering the gut-lung axis. By evaluating the potential mechanisms, new therapeutic targets and potential therapeutic modalities for bronchopulmonary dysplasia can be identified from a microecological perspective.

show abstract

mentioning

confidence: 99%

Gut microbiota and bronchopulmonary dysplasia

Yang

Dong

2021

Pediatric Pulmonology

View full text Add to dashboard Cite

show abstract

“…TLR4-NF-κB axis widely affected the occurrence and development of acute lung injury [25]. Multiple studies provided a number of drugs which could improve acute lung injury of patients through TLR4-NF-κB axis [26].…”

Section: Discussionmentioning

confidence: 99%

“…For an example, Madecassoside could protect against LPS-induced ALI through suppressing TLR4/NF-κB activation [27]. Gut microbiota could alleviate LPS-induced ALI by regulating the TLR4/NF-κB pathway [25]. Additionally, miR17 also inhibited the inflammatory response in lipopolysaccharide induced ALI via this pathway [28].…”

Section: Discussionmentioning

confidence: 99%

Icariside II regulates TLR4/NF-κB signaling pathway to improve septic lung injury

2021

View full text Add to dashboard Cite

Sepsis is caused by the inadequate response to infection and may eventually lead to fatal organ dysfunction and a high mortality rate. Acute lung injury (ALI) caused by sepsis is an important cause of its high mortality, so effective treatment drugs are urgently needed. Icariside II (ICA II) is derived from Epimedii, a ubiquitous biological flavonoid compound. ICA II has shown multiple biological activities. ICA II alleviates LPS-induced neuroinflammation by inhibiting the TLR4 / MyD88 /NF-κB pathway, however, the possible role of icaridinin II in sepsis induced acute lung injury remains unclear. Herein, we developed a sepsis-related ALI mice model induced by LPS treatment, and found Icariside II ameliorated sepsis-related acute lung injury of mice induced by LPS. Our data further confirmed that Icariside II inhibited the inflammatory response in sepsis-related ALI mice, and ameliorated oxidative stress injury. We further revealed Icariside II inhibited the apoptosis of lung cells via TLR4-NF-κB axis. Our data therefore provided a promising therapeutic drug for the treatment of sepsis-induced ALI.

show abstract

“…Similarly, Jia Tang et al. found that intestinal microbiota dysbiosis could modulate the TLR4/NF-kB signaling pathway in pulmonary immunity, subsequently motivating oxidative stress and inflammation to be involved in lung pathology by regulating the intestinal barrier ( 80 ).…”

Section: Possible Mechanisms Of Gut Microbiota Causing Lung Cancermentioning

confidence: 99%

The Role of Gut Microbiota in Lung Cancer: From Carcinogenesis to Immunotherapy

et al. 2021

View full text Add to dashboard Cite

The influence of microbiota on host health and disease has attracted adequate attention, and gut microbiota components and microbiota-derived metabolites affect host immune homeostasis locally and systematically. Some studies have found that gut dysbiosis, disturbance of the structure and function of the gut microbiome, disrupts pulmonary immune homeostasis, thus leading to increased disease susceptibility; the gut-lung axis is the primary cross-talk for this communication. Gut dysbiosis is involved in carcinogenesis and the progression of lung cancer through genotoxicity, systemic inflammation, and defective immunosurveillance. In addition, the gut microbiome harbors the potential to be a novel biomarker for predicting sensitivity and adverse reactions to immunotherapy in patients with lung cancer. Probiotics and fecal microbiota transplantation (FMT) can enhance the efficacy and depress the toxicity of immune checkpoint inhibitors by regulating the gut microbiota. Although current studies have found that gut microbiota closely participates in the development and immunotherapy of lung cancer, the mechanisms require further investigation. Therefore, this review aims to discuss the underlying mechanisms of gut microbiota influencing carcinogenesis and immunotherapy in lung cancer and to provide new strategies for governing gut microbiota to enhance the prevention and treatment of lung cancer.

show abstract

Effect of gut microbiota on LPS-induced acute lung injury by regulating the TLR4/NF-kB signaling pathway

Cited by 257 publications

References 36 publications

Gut microbiota and bronchopulmonary dysplasia

Gut microbiota and bronchopulmonary dysplasia

Icariside II regulates TLR4/NF-κB signaling pathway to improve septic lung injury

The Role of Gut Microbiota in Lung Cancer: From Carcinogenesis to Immunotherapy

Contact Info

Product

Resources

About